Amanote Research

Amanote Research

    RegisterSign In

Hyperphosphatemia in Chronic Kidney Disease

Medical Council
doi 10.21518/2079-701x-2019-16-78-85
Full Text
Open PDF
Abstract

Available in full text

Date

October 9, 2019

Authors
S. A. MartynovM. Sh. Shamkhalova
Publisher

Remedium, Ltd.


Related search

Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease

Drugs
Pharmacology
2018English

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in Chronic Kidney Disease

Kidney International Reports
Nephrology
2018English

The Management of Hyperphosphatemia by Lanthanum Carbonate in Chronic Kidney Disease Patients

International Journal of Nephrology and Renovascular Disease
Nephrology
2012English

Hyperphosphatemia in Chronic Kidney Disease: Patient Characteristics and Dialysis Mortality During the First Year of Dialysis

Journal of Nephrology & Therapeutics
2012English

Puk19 - Cost-Utility of Sucroferric Oxyhydroxide for the Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients Undergoing Dialysis in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Chronic Kidney Disease

The Professional Medical Journal
2018English

Dyslipidemia in Chronic Kidney Disease

Journal of Evolution of Medical and Dental sciences
2013English

Nutrition in Chronic Kidney Disease

Nutricion Hospitalaria
MedicineNutritionDietetics
2019English

Oxidants in Chronic Kidney Disease

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy